HRT Claims Jump 228% Among Canadian Women 45–54 as Menopause Treatment Surges: Manulife

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

A 228% jump is the kind of number that demands attention, but the story behind it is bigger than a spike in prescription claims. Manulife Canada says hormone replacement therapy claims among women aged 45 to 54 rose 228% over five years, with the strongest growth occurring recently. The increase lands in the age range when many women are moving through perimenopause or menopause, often while holding senior roles, raising families, caring for parents, or juggling all three.

The surge points to a change in how menopause is being discussed and treated in Canada. It also raises important questions about what HRT can help with, why use fell so sharply after the early 2000s, how medical guidance has evolved, and what employers and benefits plans can do as more women seek care.

What the 228% Jump Actually Measures

Manulife’s new figure comes from aggregate claims data in its Canadian Group Benefits business. Over five years, claims tied to HRT among women aged 45 to 54 rose 228%. The increase was not confined to that group: claims among women aged 35 to 44 rose 46%, while those among women aged 55 to 64 increased 66%. Manulife also said the strongest growth across age groups occurred during the most recent two years, suggesting the pace of uptake has accelerated.

That distinction matters. A 228% increase in claims does not mean 228% more Canadian women overall are using HRT, nor does it establish a national treatment rate. It reflects activity within Manulife’s covered population, and the release does not publish raw claimant counts. Still, the direction is notable. In 2024, Manulife had already reported a 20.7% rise in HRT use among women aged 45 to 65 from 2020 to 2023.

Why Ages 45–54 Sit at the Centre of the Shift

The concentration of growth among women 45 to 54 is not surprising biologically. Federal Canadian menopause guidance places the average age of menopause at about 52, while the Canadian Centre for Occupational Health and Safety says menopause commonly occurs in the 40s or 50s. Perimenopause, the transition leading to the final menstrual period, often begins earlier and can involve years of changing hormone levels and symptoms before menopause is formally reached after 12 months without a period.

That means a woman can seek treatment well before age 52 and may still need symptom management afterward. The 45-to-54 bracket therefore captures many people moving through the transition. It is also a life stage that often coincides with demanding professional and family responsibilities. A sleepless night caused by hot flashes, for example, does not stay separated from a morning presentation, a commute or caregiving duties. Manulife’s age pattern fits that real-world overlap.

Menopause Is Far More Than Hot Flashes

Public understanding of menopause has often centred on hot flashes, but the symptom picture can be much broader. Canadian occupational-health guidance lists sleep problems, mood changes, bladder issues, vaginal changes, joint pain and difficulty concentrating. The Menopause Foundation of Canada reported in its 2022 research that 95% of respondents experienced menopausal symptoms, while many were unaware that issues such as urinary tract infections, heart palpitations, anxiety, depression and memory problems could be connected to the transition.

That knowledge gap can delay care because symptoms do not always arrive as an obvious package. Someone may first seek help for insomnia, anxiety or urinary symptoms without linking them to perimenopause. The foundation also found that fewer than one-quarter of respondents said their family physician had proactively discussed menopause. Greater public discussion can translate into more treatment claims: recognizing a symptom is often the first step toward asking whether it can be managed.

The 2002 Study That Changed HRT for a Generation

Any discussion of today’s HRT rebound has to account for 2002. That year, the estrogen-plus-progestin arm of the U.S. Women’s Health Initiative was stopped early after researchers found that, for the regimen studied, overall risks exceeded benefits. The findings included higher rates of coronary heart disease, stroke, pulmonary embolism and invasive breast cancer, alongside fewer hip fractures and colorectal cancers. The trial involved women aged 50 to 79 and tested conjugated equine estrogen with medroxyprogesterone acetate.

The reaction reshaped prescribing far beyond the trial. Later research tracking women before and after the WHI announcement found that initiation of menopausal hormone therapy fell from 8.6% to 2.8%, while continuation dropped from 84% to 62%. The decline also reached younger symptomatic women, even though their circumstances could differ from the average WHI participant. The result was a generation of patients and clinicians who approached hormone therapy with heightened caution.

Clinical Guidance Has Become More Nuanced

Clinical guidance is more nuanced than a simple “safe” or “unsafe” label. The Menopause Society’s 2022 position statement says hormone therapy remains the most effective treatment for vasomotor symptoms, including hot flashes and night sweats, and for genitourinary syndrome of menopause. It also has a role in preventing bone loss and fractures. For healthy symptomatic women younger than 60 or within 10 years of menopause onset who lack contraindications, the organization describes the benefit-risk balance as favourable.

Canadian federal clinical guidance uses a similar framework, recommending hormone therapy as a first-line option for troublesome vasomotor symptoms in people younger than 60 or less than 10 years beyond menopause when no contraindications are present. The change is not that past risks disappeared; it is that timing, age, medical history, dose, route and hormone combination are weighed more carefully. That individualized approach can make clinicians more comfortable discussing HRT with suitable patients.

HRT Is a Family of Treatments, Not One Drug

HRT is discussed as if it were one medication, but it is understood as a family of treatments. Systemic estrogen can be delivered orally or through the skin, such as patches or gels, and is used for symptoms affecting the whole body, such as hot flashes and night sweats. Local low-dose vaginal estrogen is used differently, mainly for genitourinary symptoms such as vaginal dryness, painful intercourse or urinary problems, with less hormone reaching the bloodstream than with systemic therapy.

Whether progesterone or another progestogen is needed also depends on anatomy and regimen. In women with an intact uterus who use systemic estrogen, a progestogen is added to protect the endometrium from estrogen-driven overgrowth. Route and formulation matter because they can change the balance of benefits and risks. The Menopause Society notes that risk varies with type, dose, duration and route, so treatment is matched to symptoms, health profile and goals.

More Use Does Not Mean HRT Is Right for Everyone

The rise in claims should not be read as a signal that every symptomatic woman should start HRT. Canadian clinical guidance lists situations in which systemic hormone therapy may be inappropriate, including unexplained vaginal bleeding, acute liver dysfunction, a history of certain estrogen-sensitive cancers, previous stroke or thromboembolic disease, and high cardiovascular risk. Age and time since menopause matter because absolute risks of coronary disease, stroke, blood clots and dementia are higher when therapy is initiated later.

Even among candidates for treatment, route can influence risk. Evidence reviews have found oral estrogen more strongly associated with venous thromboembolism than transdermal estrogen, though evidence varies by population and formulation. A proper assessment involves more than asking whether symptoms are severe. Clinicians may consider personal and family history, cardiovascular risk, cancer history, bleeding patterns and other factors before recommending a regimen. Rising use can coexist with screening; the two are not contradictory.

Non-Hormonal Options Still Matter

Hormone therapy is not the only evidence-based route through menopause. For people who cannot take hormones or prefer not to, The Menopause Society’s 2023 nonhormone position statement recommends options for vasomotor symptoms, including SSRIs and SNRIs, gabapentin, fezolinetant, cognitive behavioural therapy and clinical hypnosis, with evidence strength varying by treatment. Canadian federal guidance also lists non-hormonal prescription approaches, including antidepressant-class medications and gabapentin.

This matters because “more menopause treatment” should not be reduced to “more HRT.” A person with a history that makes systemic estrogen unsuitable may still have effective options, and someone whose main problem is vaginal dryness may be treated differently from someone waking with night sweats. The best plan can change as symptoms, health conditions and preferences change. The surge in HRT claims is therefore best understood as one part of a broader shift toward active menopause management, not proof that one therapy is the default answer.

Menopause Has a Measurable Workplace Cost

Menopause is a personal health transition, but its effects can spill into the workplace. A 2023 Menopause Foundation of Canada report estimated that unmanaged symptoms cost the Canadian economy $3.5 billion yearly. Its analysis attributed $237 million to lost productivity and $3.3 billion to lost income from reduced hours, lower pay or leaving the workforce, while estimating 540,000 lost workdays annually. It said more than two million working women in Canada were between 45 and 55.

The same research found that 32% of respondents said symptoms affected job performance, while 24% said they hid symptoms at work. The figures make the Manulife claims increase relevant to employers and clinicians. Occupational-health guidance recommends supports such as flexible hours, cool water, washroom access, temperature control where possible, and time for medical appointments. Benefits may pay for treatment, but workplace design can determine whether symptoms are manageable on the job.

Benefits Coverage Can Shape Access to Care

Employer health benefits sit at the intersection of this trend because coverage can affect treatment access. Manulife said in 2024 that most prescription drug benefits include HRT and other medications used for menopause symptoms, and that such coverage is standard in its Group Benefits plans with extended health care coverage. In 2026, the insurer also said more than 1.4 million Group Benefits members had complimentary access to Maven’s menopause program through expanded virtual women’s-health support.

That expansion is commercially relevant to Manulife, so its claims data should be read with that context. But it also shows how benefits providers are responding to demand that was once less visible. For an employee, access may require several pieces to align: a clinician who recognizes symptoms, a prescription suited to the individual risk profile, drug coverage, and enough flexibility to attend appointments or adjust treatment. Claims can rise when practical barriers fall.

What the Surge Signals—and What It Cannot Prove

The key takeaway from the 228% figure is not that menopause suddenly became more common. The transition was already there. What is changing is the likelihood that symptoms are recognized, discussed and treated through channels captured by insurance claims. Manulife links the increase to awareness and treatment uptake, while its earlier data showed rising use before the latest acceleration. Its September release does not provide raw national counts or a population-weighted prevalence estimate.

Therefore, the number is best treated as a signal rather than a census of Canadian menopause care. It points toward a shift in behaviour among insured women, especially those aged 45 to 54, but national prescribing data would be needed to gauge the full scale of change. What is clear is that menopause care has moved further into mainstream health, workplace and benefits conversations, with treatment increasingly framed around individualized evidence rather than decades-old assumptions.

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.